Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Aquestive Therapeutics Inc | 24 |
| 2 | The University of Texas System | 19 |
| 3 | University of Alabama System | 11 |
| 4 | Celanese Corp | 9 |
| 5 | Daiichi Sankyo Co Ltd | 8 |
| 6 | Eli Lilly and Co | 6 |
| 7 | Ascendis Pharma AS | 5 |
| 8 | Scripps Research Institute | 5 |
| 9 | Novartis AG | 4 |
| 10 | Tolmar Holding Inc | 4 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 120 |
| 2 | A61P | Therapeutic activity (drug indications) | 76 |
| 3 | A61M | Devices for introducing media into the body | 27 |
| 4 | C07D | Heterocyclic compounds | 17 |
| 5 | Y02A | Climate change adaptation | 16 |
| 6 | Y10T | Cross-reference (technical subjects) | 15 |
| 7 | A01N | Preservation of bodies; biocides; pest repellents | 14 |
| 8 | C08L | Polymer compositions (blends) | 14 |
| 9 | B81B | 11 | |
| 10 | B81C | 11 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | 2017 | Wave Life Sciences Pte Ltd | 149 |
| DHA-pharmaceutical agent conjugates of taxanes | 1998 | Daiichi Sankyo Co Ltd | 360 |
| DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | 2011 | Ascendis Pharma AS | 179 |
| Modified release composition for highly soluble drugs | 2012 | Torrent Pharmaceuticals Ltd | 164 |
| Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | 2012 | Torrent Pharmaceuticals Ltd | 160 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Marlene L. Cohen | Eli Lilly (United States) | 4 |
| 2 | J. S. Gidda | Eli Lilly (United States) | 3 |
| 3 | Rex Y. Wang | Stony Brook University | 2 |
| 4 | Barbara J. Ring | Eli Lilly (United States) | 2 |
| 5 | Yoshio Minabe | Stony Brook University | 2 |
| 6 | C. John Parli | Eli Lilly (United States) | 2 |
| 7 | David W. Robertson | Eli Lilly (United States) | 2 |
| 8 | Charles R. Ashby | Stony Brook University | 2 |
| 9 | Steven Wrighton | Eli Lilly (United States) | 2 |
| 10 | William B. Lacefield | Eli Lilly (United States) | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| The human drug metabolizing cytochromes P450 | 1996 | 166 | Pharmacogenetics and Drug Metabolism |
| Serotonergic modulation of cat bladder function before and after spinal transection | 1995 | 40 | Pain Mechanisms and Treatments |
| LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity. | 1990 | 40 | Gastrointestinal motility and disorders |
| The effect of acute and chronic LY 277359, a selective 5-HT3 receptor antagonist, on the number of spontaneously active midbrain dopamine neurons | 1991 | 32 | Schizophrenia research and treatment |
| In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A. | 1994 | 25 | Insect Pheromone Research and Control |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of zatosetron maleate?
Which organizations hold the most patents related to zatosetron maleate?
What research topics are covered by the published papers on zatosetron maleate?
What are the primary patent classification codes for zatosetron maleate inventions?
How has patent activity for zatosetron maleate changed over recent years?